Amitriptyline / Perphenazine
Amitriptyline/Perphenazine is a combination medication that merges a tricyclic antidepressant with a typical antipsychotic. This combination is primarily prescribed for the treatment of moderate to severe anxiety and depression, particularly when symptoms of agitation or anxiety accompany depressive episodes. The medication works to address both the emotional and anxiety-related symptoms that can occur together.
A combined antidepressant-antipsychotic medication used to treat anxiety and depression with associated agitation.
Key facts at a glance
- RxNorm
- 1012360
- Generic
- Amitriptyline / Perphenazine
- Class
- multi-ingredient
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
This medication is primarily used to treat moderate to severe anxiety and major depressive disorder, especially when symptoms of tension, agitation, or anxiety are prominent alongside depression. It may be prescribed when single-agent therapy has not provided adequate symptom control.
Amitriptyline works by increasing levels of serotonin and norepinephrine in the brain through reuptake inhibition. Perphenazine blocks dopamine D2 receptors, which helps reduce agitation and anxiety. Together, these mechanisms target both the mood and anxiety components of the conditions being treated.
This medication may cause significant drowsiness and should be used with caution when operating machinery or driving. It has anticholinergic effects including dry mouth, constipation, and urinary retention. Avoid alcohol and inform your doctor of all medications, as serious interactions can occur. Not recommended for use in elderly patients with dementia-related psychosis due to increased mortality risk.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy